Investment Rating - The report maintains a "Buy" rating for the company [1][8]. Core Insights - The company achieved record high revenue and profit, driven by significant growth in its sub-healthcare segment [5]. - The company's revenue for H1 2025 reached 1.459 billion RMB, a year-on-year increase of 28.2%, with a net profit of 171 million RMB, up 35.5% year-on-year [5]. - The "internal + external" strategy is expected to continue driving growth, with projected revenues of 3 billion RMB in 2025, 3.4 billion RMB in 2026, and 3.7 billion RMB in 2027 [5]. Financial Performance - The company reported a gross margin of 49.3% for H1 2025, an increase of 2.3 percentage points year-on-year [5]. - The operating cash flow for H1 2025 was 410 million RMB, reflecting an 84.4% increase year-on-year [5]. - As of June 30, 2025, the company had cash and cash equivalents totaling 2 billion RMB, a 27.5% increase year-on-year [5]. Business Segments - The beauty and wellness services segment generated revenue of 807 million RMB in H1 2025, a year-on-year increase of 29.6% [5]. - The medical beauty segment reported revenue of 499 million RMB, up 13.0% year-on-year, driven by increased patient visits [5]. - The sub-healthcare services segment saw remarkable growth, with revenue reaching 154 million RMB, a 107.8% increase year-on-year [5]. Membership Growth - The company experienced a 46.5% year-on-year increase in active members, reaching 120,000 members [5]. - The number of visitors to direct-operated stores exceeded 920,000 in H1 2025, representing a 47.8% increase year-on-year [5]. Future Projections - The company forecasts revenue growth of 18% in 2025, followed by 10% in 2026 and 9% in 2027 [5]. - The projected net profit for 2025 is 300 million RMB, with expected growth rates of 34% in 2025, 15% in 2026, and 15% in 2027 [5].
美丽田园医疗健康（02373）：动态点评：收入利润再创新高，亚健康医疗增速亮眼